Doxorubicin is an anthracycline antitumor antibiotic and one of the most widely used injectable chemotherapeutics in veterinary medicine. It acts on cancer cells through a battery of mechanisms, including DNA intercalation, inhibition of DNA and RNA polymerases, inhibition of topoisomerase II, DNA alkylation, and the generation of reactive oxygen species. That versatility makes it a staple against many canine malignancies, both as a single agent and within multi-drug protocols. But its toxicity profile is equally well known. Gastrointestinal adverse events and myelosuppression, the suppression of bone marrow activity, are the dose-limiting toxicities, and dogs receiving doxorubicin as a single agent experience gastrointestinal side effects more frequently than with most other intravenous chemotherapeutics.

The problem with the current standard lies in its assumptions. Doses of doxorubicin, like many chemotherapies, are calculated using body surface area, a practice originally adopted to normalize doses across species on the grounds that surface area better reflects basal metabolic rate than body weight alone. Yet body surface area cannot account for the factors that actually determine how much drug circulates in a patient: distribution, metabolism, and excretion. The evidence that something is amiss has been accumulating for years. Smaller dogs suffer more severe adverse events when dosed by body surface area, which is why dogs under 15 kilograms are typically treated with a weight-based dose of 1 milligram per kilogram instead. The formula, in short, is imperfect.

Pharmacokinetics offers a way out. Rather than asking how much drug was administered, pharmacokinetic-guided dosing asks how much drug the patient actually absorbed and retained over time, quantified as the area under the drug concentration-time curve, or AUC. Previous work in canine patients demonstrated that predicted doxorubicin AUC correlates with neutropenia, the dangerous drop in neutrophils that marks bone marrow suppression, as well as with total white blood cell counts and the surviving fraction of neutrophils at the nadir, the lowest point of the count. Human medicine has already capitalized on this logic. Pharmacokinetic-guided dosing of docetaxel reduced variability in bone marrow suppression by up to 50 percent, and individualized fluorouracil dosing in metastatic colorectal cancer significantly improved objective response rates compared with conventional dosing.

The Davis team, led by Sridhar Madan Veluvolu together with Robert B. Rebhun, Jaeyoung Kim, and Luke Anthony Wittenburg, built on a tool developed earlier in their laboratory: a limited sampling model that predicts total doxorubicin exposure from just three blood samples. Under the protocol, dogs received a standard 30 milligrams per square meter dose by 20-minute intravenous infusion, and blood was drawn at five, 45, and 60 minutes after the infusion ended. Serum doxorubicin concentrations were measured with a validated liquid chromatography tandem-mass spectrometry assay, linear from 10 to 750 nanograms per milliliter, and plugged into a weighted equation that estimates the AUC over the first six hours. The elegance of the approach is its practicality: three time points instead of an exhaustive sampling series makes prospective clinical use feasible.

The prospective study ran from June 2021 to August 2022 at the UC Davis Veterinary Medical Teaching Hospital, enrolling tumor-bearing dogs at least 15 kilograms in weight with favorable performance scores and no cardiac dysfunction or multidrug-resistance gene mutations. Ten dogs met the criteria, but three were withdrawn after a single dose because of owner-perceived adverse events, leaving seven patients who completed three full cycles of doxorubicin with complete blood counts at baseline and at the seven-day nadir after each dose. Owners filled out standardized questionnaires about gastrointestinal signs after every treatment and were asked to keep their pets on a consistent diet to make those observations as comparable as possible.

The headline result is stark. Measured and dose-normalized doxorubicin concentrations varied nearly tenfold between patients at the sampled time points, and there was no significant correlation between the total milligram dose a dog received and its predicted AUC. When the coefficient of variation was calculated after normalizing for dose, the average within-patient variability across three cycles was just 4.7 percent, while the average between-patient variability was 25.4 percent, a difference that was highly statistically significant. Before dose normalization the within-patient figure was 10.7 percent against 22.5 percent between patients. Notably, the within-patient variability observed in these dogs, ranging from 2.8 to 9 percent, is lower than the 6 to 59 percent reported in humans, while the between-patient variability in dogs was tighter than the 37 to 93 percent seen in human studies.

The model also proved its worth as a predictive instrument. Although no significant relationship emerged between predicted AUC and absolute neutrophil counts across all data points, the picture sharpened when the analysis focused on dogs whose seven-day neutrophil counts were genuinely lower than baseline, suggesting the true nadir had been captured. For those patients, higher exposure correlated significantly with a lower surviving fraction of neutrophils. The limited sampling model, using baseline neutrophil count and predicted AUC together, successfully predicted the absolute nadir neutrophil count with a mean prediction error of just 3.3 percent. Three neutropenic events were captured during the study, two of which occurred at the highest predicted exposures, and one patient who received a 25 percent dose reduction after severe neutropenia subsequently showed a 25 to 32 percent drop in exposure, an encouraging hint that the model tracks dose changes faithfully.

The gastrointestinal findings add a patient-centered dimension. Using owner-reported scores, the researchers found that higher predicted AUC correlated significantly with decreased appetite and increased nausea, though not with vomiting or diarrhea, and no significant relationship emerged for composite gastrointestinal scores. The authors caution that owner scoring of subjective signs carries inherent bias, but the correlations suggest that the patients with the highest drug exposure are also the ones feeling the worst, a pattern that personalized dosing could potentially flatten. The study had clear limitations, including its small size of seven completers, strict eligibility criteria that may not represent the broader population of treated dogs, and unexplored genetic factors, since doxorubicin disposition involves influx and efflux transporters and metabolizing enzymes whose variants in dogs remain poorly characterized.

What comes next is the crucial question of targets. The researchers emphasize that no one yet knows what AUC a dog should hit to maximize tumor response while minimizing toxicity, and that target may differ from patient to patient. In human docetaxel therapy, AUC-guided dose adjustment dramatically increased the proportion of patients within the therapeutic window and improved disease control rates. Neutropenia itself may serve as a double-edged biomarker, since in canine lymphoma it has been associated with longer remission and survival times, hinting that the right amount of bone marrow suppression may signal effective dosing. For now, the Davis team’s message is simple and provocative: the same dose produces wildly different exposures in different dogs, but each dog is remarkably consistent with itself. That consistency is precisely what makes individualized dosing achievable, and the first treatment cycle may be all the information a clinician needs to get there.

Subject of Research: Pharmacokinetic variability of doxorubicin exposure in dogs with cancer using a limited sampling model

Article Title: Comparison of interpatient and intrapatient variability in doxorubicin exposure using a validated limited sampling model in dogs with cancer

Article References: Veluvolu, S. M., Rebhun, R. B., Kim, J., & Wittenburg, L. A. (2025). Comparison of interpatient and intrapatient variability in doxorubicin exposure using a validated limited sampling model in dogs with cancer. Veterinary Oncology, 2(1), Article 24. https://doi.org/10.1186/s44356-025-00038-z

Image Credits: AI Generated

DOI: 10.1186/s44356-025-00038-z

Keywords: doxorubicin, veterinary oncology, pharmacokinetics, limited sampling model, chemotherapy dosing, body surface area, neutropenia, AUC, dogs, adverse events, personalized medicine, canine cancer

The HeartMate 3, a fully magnetically levitated continuous-flow pump, has become a workhorse of advanced heart failure therapy worldwide, offering durable support both as a bridge to transplantation and as destination therapy. Because the pump maintains a constant flow through the circulatory system, its external controller continuously estimates flow and triggers alarms when values fall below a preset low flow limit, or LFL. That alarm serves as an early warning for potentially dangerous conditions such as pump thrombosis, inflow obstruction, hypovolemia, or arrhythmias. The factory-standard setting is 2.5 liters per minute, but clinicians have increasingly recognized that some patients—particularly those of smaller body habitus—may run baseline flows close enough to that threshold that nuisance alarms become a daily occurrence, eroding quality of life and prompting careful discussions about whether the alarm limit can safely be lowered.

In a retrospective observational study published in the Journal of Artificial Organs, a team led by Hiroshi Nishioka of the National Cerebral and Cardiovascular Center in Suita, Osaka, and Takuma Sato of the same institution’s Department of Transplant Medicine set out to determine which preoperative characteristics predicted the need for postoperative replacement of the standard controller with one configured to a low flow limit of 2.0 liters per minute. The researchers analyzed 127 patients who underwent primary HeartMate 3 implantation at their center between June 2019 and March 2025. Of these, 78 patients maintained the standard 2.5 liter-per-minute controller throughout follow-up, while 49 required replacement with a controller set to the lower 2.0 liter-per-minute threshold.

The comparison between the two groups revealed a striking pattern. Patients who ultimately needed the lower alarm limit were significantly smaller across every anthropometric measure examined: they were shorter, weighed less, had lower body mass index, and, most consequentially, had smaller body surface area. They also tended to have a shorter history of heart failure before implantation. By contrast, the study found no significant differences between the groups in a broad battery of clinical, echocardiographic, and hemodynamic variables, suggesting that the conventional parameters clinicians often scrutinize before implantation—measures of cardiac function and pumping performance—did not separate the two groups.

To move from association to prediction, the researchers applied multivariate logistic regression, a statistical technique that evaluates each candidate variable’s independent contribution while holding the others constant. When all the clinical, laboratory, echocardiographic, and hemodynamic measurements were weighed together, body surface area emerged as the sole independent predictor of postoperative controller replacement. The effect size was dramatic: each unit increase in body surface area was associated with an odds ratio of 0.03, meaning that larger patients were overwhelmingly less likely to require the lower alarm limit. The 95 percent confidence interval ranged from 0.00 to 0.60, and the result reached statistical significance with a p-value of 0.022.

The team then used receiver operating characteristic curve analysis to translate that statistical association into a clinically usable threshold. This method plots a test’s sensitivity against its specificity across all possible cutoff values, allowing researchers to identify the value that best discriminates between groups. A preoperative body surface area of 1.43 square meters proved to be the optimal cutoff, yielding an area under the curve of 0.74—indicating moderate discriminatory power—with a specificity of 89.7 percent and a sensitivity of 38.8 percent. In practical terms, a patient whose body surface area falls below 1.43 square meters is very likely to be among those who will need the lower alarm limit, while the relatively modest sensitivity means that some patients above the cutoff will still require it. The authors are transparent about this trade-off: the threshold is highly specific but only moderately sensitive, making it best suited for identifying patients who clearly warrant a 2.0 liter-per-minute controller from the outset.

The clinical logic behind lowering the alarm limit in smaller patients rests on the physiology of continuous-flow circulatory support. Pump flow scales with the metabolic demands of the body, and smaller patients simply generate lower absolute flows at any given support setting. When baseline flows hover near 2.5 liters per minute, the standard alarm threshold produces frequent false alarms during routine activity, dehydration, or minor hemodynamic shifts. Frequent alarms are not merely an annoyance; studies of left ventricular assist device patients have linked alarm burden to anxiety, sleep disruption, and reduced quality of life, and they can lead patients and caregivers to become desensitized to alerts, potentially delaying recognition of genuine emergencies. Lowering the limit to 2.0 liters per minute preserves the protective function of the alarm for truly dangerous low-flow states while eliminating the constant noise of alerts triggered by the patient’s normal operating range.

Until now, however, the decision to swap the standard controller for a 2.0 liter-per-minute version has typically been reactive: clinicians implant the device with factory settings, observe alarm behavior over weeks or months, and then arrange for controller replacement in those who struggle. Each replacement carries practical costs—additional hospital visits, device reprogramming, patient education, and the logistics of exchanging a life-sustaining external component. The study’s authors argue that a proactive approach, guided by the 1.43 square meter body surface area threshold, could spare many smaller patients an unnecessary second procedure while ensuring that the alarm system remains calibrated to their physiology from day one. Because the cutoff is derived from a measurement taken routinely at every preoperative evaluation, implementing it would require no additional testing, only a change in configuration practice.

The findings come amid rapid growth in mechanical circulatory support. The most recent annual report from the Society of Thoracic Surgeons Interagency Registry for Mechanically Assisted Circulatory Support documented expanding use of the HeartMate 3 across age groups, including growing experience in pediatric and small-statured patients through networks such as the Advanced Cardiac Therapies Improving Outcomes Network. As the device is implanted in increasingly diverse populations, individualizing device settings becomes more pressing. The Japanese cohort studied here reflects a national experience in which body size distributions differ from those in Western registries, and the authors caution that their results derive from a single center; validation in larger, multi-center and ethnically diverse cohorts will be needed before the 1.43 square meter threshold can be adopted as a universal standard.

Nevertheless, the elegance of the result lies in its simplicity. In an era when artificial hearts are guided by sophisticated algorithms and magnetically levitated rotors, one of the most useful predictors of device configuration turns out to be a number calculated from height and weight. For clinicians implanting the HeartMate 3, the message is concrete: check the body surface area before surgery, and for patients below roughly 1.43 square meters, consider reaching for the 2.0 liter-per-minute controller at the start. For the growing community of patients living with these pumps, it could mean fewer alarms, fewer controller exchanges, and a device experience better matched to the bodies it sustains.

Subject of Research: Preoperative prediction of low flow limit controller configuration after HeartMate 3 implantation

Article Title: Preoperative predictors of low flow limit controller configuration following HeartMate 3 implantation

Article References: Nishioka, H., Sato, T., Komiyama, M., Iwanaga, K., Tonai, K., Kitahata, N., Takahashi, Y., Miyagawa, S., Sawada, K., Yotsuida, H., Tadokoro, N., Fukushima, S., Fujita, T., Fujisato, T., & Tsukamoto, Y. (2026). Preoperative predictors of low flow limit controller configuration following HeartMate 3 implantation. Journal of Artificial Organs, 29(4), Article 62. https://doi.org/10.1007/s10047-026-01590-7

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01590-7

Keywords: HeartMate 3, left ventricular assist device, body surface area, low flow limit, low-flow alarm, controller configuration, advanced heart failure, mechanical circulatory support, quality of life, cardiac surgery, LVAD, predictive threshold